For decades, a diagnosis of metastatic pancreatic cancer carried with it a quiet finality — the disease, driven in nine of ten cases by a single rogue genetic switch, has resisted nearly every therapeutic advance medicine could offer. Now, a once-daily pill called daraxonrasib has doubled median survival in patients who had exhausted all other options, not by overwhelming the body with toxicity, but by binding to the very molecular machinery that tells cancer cells to keep dividing. It is not a cure, but in a disease where months are everything, it represents something oncology has rarely been
Daraxonrasib doubles survival in advanced pancreatic cancer, offering new hope
Pancreatic cancer patients with metastatic disease who have exhausted standard chemotherapy options now have access to a treatment that extends median survival and improves quality of life.